U.S. Food and Staples Retail Stock News

Over the past week, uniQure N.V. completed an upsized US$225,000,003 follow-on equity offering of 4,945,055 ordinary shares at US$45.50 each, shortly after reporting initial AMT-260 epilepsy data and confirming FDA support for using three-year AMT-130 results as the basis for an accelerated approval filing in Huntington’s disease. An interesting angle is how uniQure is pairing early but encouraging central nervous system gene therapy readouts with an expanded share capital base to fund...

In June 2026, Accenture reported higher third-quarter revenue of US$18.72 billion and net income of US$2.34 billion, while trimming full-year 2026 revenue guidance to 3%–4% growth in local currency and flagging booking softness, AI-related demand shifts, and Middle East disruptions. At the same time, Accenture moved to reinforce its AI- and software-centric positioning with new launches like Accenture Edge for mid-market clients, major OT cybersecurity acquisitions, and engineering...

Trade tensions around the US-Mexico-Canada Agreement, rising Chinese vehicle production in Mexico and Canada, and talk of new tariffs are putting a fresh spotlight on North American auto parts and supply chain stocks. These shifts could matter for anything tied to vehicle production, cross border sourcing, and joint ventures with Chinese automakers. For investors, the question is which stocks might benefit if capital and production continue to build in the region, and which could face higher...

First Citizens BancShares (FCNC.A) has drawn fresh attention after its Silicon Valley Bank division announced a partnership with Corgi Insurance to offer AI driven risk management and digital insurance solutions to startup clients. See our latest analysis for First Citizens BancShares. The new AI driven insurance partnership arrives at a time when First Citizens BancShares’ share price is US$2,089.21 per share and has delivered a 90 day share price return of 13.81%, alongside a 1 year total...

Zimmer Biomet Holdings (ZBH) recently reaffirmed its 1% to 3% revenue growth outlook while lifting earnings guidance, highlighting early benefits from its commercial overhaul and increased focus on robotics solutions. See our latest analysis for Zimmer Biomet Holdings. Zimmer Biomet Holdings’ recent guidance update comes as the stock shows modest positive momentum, with a 7.76% 1 month share price return and a 3.40% 7 day share price return, set against a 5 year total shareholder return that...

Saia (SAIA) has rolled out its Saia REV initiative and opened new terminals in Duluth, Minnesota, and Columbia, Missouri, giving investors fresh operational data points to weigh against recent share performance. See our latest analysis for Saia. These network investments and the Saia REV rollout come after a strong run in the stock, with a 90 day share price return of 29.73% and a 1 year total shareholder return of 60.19%. This suggests momentum has been robust even as the 30 day share price...

If you are wondering whether AGNC Investment at around US$10.62 is still offering value or if most of the upside is already priced in, the starting point is understanding how the stock is being valued today. AGNC Investment has been relatively steady in the short term, with the share price up 2.3% over the last week and 1.8% over the last month. The return over the past year sits at 31.1% and the three and five year returns are 61.0% and 22.8% respectively, with the stock down 2.8% year to...

Earlier this week, Truist Financial’s Danielle Brill initiated coverage of Rapport Therapeutics with a buy rating, citing her track record over the past year as a reference point for investors. This new coverage adds another professional voice to the research pool around Rapport, which can influence how the company’s prospects are interpreted. Next, we’ll examine how this new analyst coverage from Truist Financial may shape Rapport Therapeutics’ broader investment narrative. Find 43...

Margin recovery and lower operating costs strengthen the investment case, but continued cash burn leaves execution and financing firmly in focus.

These small-cap tech stocks sit at the intersection of defense innovation and next-gen VR and AR.

Academy Sports and Outdoors (ASO) has been in focus after extending its national partnership with Boys & Girls Clubs of America and joining Uber Eats as a retail partner, expanding both community outreach and digital reach. See our latest analysis for Academy Sports and Outdoors. Despite the news around Academy Sports and Outdoors broadening its community and digital presence, the share price has been under pressure recently, with the 30 day share price return down 11.2% and the year to date...

Accelerating withdrawal requests at Ares Management’s flagship private credit fund, with 14% of investors asking to redeem in Q2 against a 5% cap, have put liquidity risk and redemption pressure in the spotlight. For anyone holding, or considering, stocks tied to retail-focused private credit vehicles, this is a clear reminder that funding structures matter as much as yield. This article explains how that news relates to three stocks exposed to the same tension between investor outflows and...

Restructuring pressures and investor exit put Westlake (WLK) in focus Antipodes Partners recently exited Westlake (WLK), citing weak global industrial demand, pressure on its Performance and Essential Materials segment, and concerns around an ongoing restructuring. The company has been contending with reduced operating rates and significant unplanned maintenance costs in this core segment, which supplies ethylene, polyethylene, PVC and other key inputs for industrial and consumer...

Teamshares (TMS) stock recently attracted investor attention after its latest trading session, with shares closing at $10.70. The move comes as investors weigh the company’s employee-ownership focused acquisition model. See our latest analysis for Teamshares. Looking beyond the latest session, Teamshares’ share price return of 3.9% year to date, supported by a 2.9% 90 day share price return, suggests modest positive momentum, while the 1 year total shareholder return is flat. If this employee...

IDEX (IEX) has drawn fresh attention after its Board approved a regular quarterly cash dividend of $0.73 per share, marking the company’s 127th consecutive quarterly payout to shareholders. See our latest analysis for IDEX. Alongside the dividend decision, IDEX has seen firm price momentum, with a 1 month share price return of 8.02%, a 3 month share price return of 22.26%, and a year to date share price return of 27.37%. The 1 year total shareholder return of 31.33% and 3 year total...

Edgewise Therapeutics recently reported positive top-line 12-week Phase 2 Part D CIRRUS-HCM results for EDG-7500 in both obstructive and nonobstructive hypertrophic cardiomyopathy, showing clinically meaningful improvements in hemodynamics, heart failure biomarkers, patient-reported outcomes and functional status, with generally well-tolerated safety. A distinctive aspect of these data is the apparent preservation of systolic function across more than 700 echocardiograms while still...

What Is Moving National HealthCare Stock Right Now? National HealthCare (NHC) has drawn investor attention recently as the stock price and valuation metrics have shifted. This is prompting a closer look at how its current market pricing compares with reported fundamentals. See our latest analysis for National HealthCare. Recent trading in National HealthCare shows strong momentum, with a 30 day share price return of 6.07%, a 90 day share price return of 25.15%, and a 1 year total shareholder...

Earlier this week at the BIO International Convention 2026 in San Diego, Thermo Fisher Scientific showcased upgrades to its Orbitrap mass spectrometry platform, new AI-powered software, and integrated laboratory solutions aimed at supporting complex research and biopharma development. This push to act as a single, AI-enabled partner across drug discovery, clinical development, and bioproduction highlights Thermo Fisher’s effort to deepen its role in end-to-end pharmaceutical workflows. We’ll...

Why ESAB’s New Board Roles Matter for Investors ESAB (ESAB) recently reshaped its board leadership, appointing Mitchell P. Rales as Executive Chair and Rhonda Jordan as Lead Independent Director. These moves focus attention on the company’s governance and ongoing transformation. For investors tracking ESAB stock, these appointments highlight how the board intends to organize oversight, clarify leadership roles, and support the existing management team as it pursues the company’s growth and...

Five Star Bancorp has opened a new full-service branch in Lodi, California, to deepen its banking support for local entrepreneurs and agribusinesses in the Central Valley. This move reinforces the bank’s focus on relationship-based lending in agriculture-rich communities, particularly vineyards and nut and cherry producers around Lodi. Next, we’ll examine how the Lodi branch opening, with its emphasis on agribusiness lending, may influence Five Star Bancorp’s investment narrative. Uncover...

Recent commentary on American Tower (AMT) is putting fresh focus on how its global tower network and data center portfolio intersect with rising 5G deployment, cloud computing demand, and AI driven workloads. See our latest analysis for American Tower. Despite the focus on 5G and AI infrastructure, American Tower’s recent share price has been under pressure. The 30 day share price return is down 8.78% and the 1 year total shareholder return is down 19.44%, pointing to fading momentum as...

BXP (BXP) stock is back in focus after the company signed a long term lease with Boston Dynamics for about 320,000 square feet at Reservoir Place in Waltham, Massachusetts. See our latest analysis for BXP. BXP’s latest leasing wins with Boston Dynamics and McDermott Will & Schulte come as momentum in the stock has recently improved, with a 30 day share price return of 8.35% and a 90 day gain of 27.69%. However, the year to date share price is still down 3.17% and the 5 year total shareholder...

LivaNova recently reported new clinical data showing that its PolySync programming algorithm increased the cumulative apnea-hypopnea index response rate to 84.5% in moderate to severe Obstructive Sleep Apnea patients treated with proximal hypoglossal nerve stimulation, with no serious treatment-emergent or device-related adverse events, based on OSPREY trial reprogramming results presented at SLEEP 2026. The findings underscore how PolySync’s simultaneous-contact stimulation and six-contact...

Earlier this month, La-Z-Boy Incorporated reported fourth-quarter 2026 sales of US$570.34 million with net income of US$33.27 million, raised its quarterly dividend for the fifth consecutive year, launched a new US$300 million share repurchase authorization, and disclosed continued activity under its long-running buyback program. Together, higher quarterly earnings, ongoing dividend growth, and a sizable new repurchase plan underscore management’s commitment to returning cash to shareholders...